Irsenontrine

DB19044InvestigationalSmall molecule

Irsenontrine is under investigation in clinical trial NCT03467152 (Study to Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies).

Mechanism: Pharmacologically active on High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
Curator reviewed
Formula / weight: C₂₂H₂₂N₄O₃ · 390.443 g/mol (avg)
Also known as: 4h-pyrazolo(4,3-c)quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4- pyridinyl)-1-((3s)-tetrahydro-3-furanyl)- · 7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-((3s)-tetrahydrofuran-3-yl)-1,5-dihydro-4h-pyrazolo(4,3-c)quinolin-4-one
Code names: E-2027 · ER-592221-00

Resolves to

Compound

UNII54QB00NNRBCAS1429509-82-9ChEMBLCHEMBL4650368

Structure

InChIKeyCKJDCNZBABIEBZ-HNNXBMFYSA-NSMILES[H][C@@]1(CCOC1)N1N=CC2=C1C1=C(NC2=O)C=C(C=C1)C1=C(C)C=NC(OC)=C1C

Targets

O76083PDE9A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Irsenontrine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account